The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing the predictive role of tumor sidedness in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) treated with first-line doublets + anti-EGFRs/bevacizumab (bev) or triplet + bev: An individual patient data pooled analysis of 10 randomized clinical trials.
 
Marco Maria Germani
No Relationships to Disclose
 
Roberto Moretto
No Relationships to Disclose
 
Arndt Stahler
Honoraria - Amgen; Daiichi Sankyo Europe GmbH; Merck KGaA; MSD; Takeda
Consulting or Advisory Role - Takeda
Research Funding - Merck KGaA (Inst)
Travel, Accommodations, Expenses - Amgen; Lilly; Merck KGaA; Pfizer; Roche
 
Tadayoshi Hashimoto
Honoraria - Cytogen; Takata Pharmaceutical
 
Federica Morano
Honoraria - Accademia Nazionale Di Medicina (ACCMED); Pierre Fabre; SERVIER
Research Funding - Incyte (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo/Astra Zeneca; Pierre Fabre; SERVIER
 
Alan Venook
Consulting or Advisory Role - Abbvie; Amgen; Eisai; Exact Sciences; Exelixis; INTERA; Pfizer
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
 
Sebastian Stintzing
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb GmbH; Daiichi Sankyo Europe GmbH; Merck KGaA; MSD; Nordic Bioscience; Pfizer; Pierre Fabre; Roche; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; CV6 Therapeutics; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Isofol Medical; Merck KGaA; MSD; Nordic Bioscience; Pierre Fabre; Roche; Seagen; SERVIER; TERUMO
Research Funding - Amgen (Inst); Merck Serono (Inst); MSD (Inst); Pierre Fabre (Inst); Roche Molecular Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - Servier (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Lilly; Merck KGaA; Pierre Fabre; Roche; Sanofi; Sirtex Medical; Takeda
 
Yoshiaki Nakamura
Consulting or Advisory Role - DAIICHI SANKYO Co., Ltd.; Exact Sciences; Gilead Sciences; Guardant Health Pte Ltd; Natera,Inc.; Premo Partners, Inc.; Roche Ltd./; Seagen,Inc.; Takeda
Speakers' Bureau - Becton Dickinson; CareNet,Inc.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health Japan Corp.; Guardant Health Pte Ltd; Hisamitsu Pharmaceutical; Merck; Miyarisan pharmaceutical; MSD K.K; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health AMEA, Inc. (Inst); Roche (Inst); Seagen,Inc. (Inst); Tempus (Inst)
 
Giacomo Di Paolo
No Relationships to Disclose
 
Francesca Battaglin
No Relationships to Disclose
 
Kathrin Heinrich
Honoraria - Amgen; Bristol-Myers Squibb; Merck KGaA; MSD; Roche Pharma AG; SERVIER; Streamedup!; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Amgen; Janssen; Merck KGaA; MSD (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen; Merck KGaA; SERVIER
(OPTIONAL) Uncompensated Relationships - DKG Krebsgesellschaft
 
Kei Muro
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); MSD (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
 
Francesca Bergamo
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Takeda; Teysuno
Speakers' Bureau - AstraZeneca; Bayer; BMS; Lilly; MSD Oncology
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis
 
Dominik Modest
Honoraria - 21up; Amgen; AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Cor2Ed; GlaxoSmithKline; IKF Klinische Krebsforschung; Lilly; Merck; Merck Serono; Onkowissen; Pierre Fabre; Regeneron; Rottapharm Biotech; Seagen; SERVIER; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Cor2Ed; GlaxoSmithKline; Incyte; Lilly; Merck Serono; Onkowissen; Pierre Fabre; Regeneron; SERVIER; Takeda
Research Funding - Amgen (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; SERVIER
 
Junpei Soeda
Employment - Takeda
 
Carlotta Antoniotti
Honoraria - Merck
Travel, Accommodations, Expenses - Merck
 
Heinz-Josef Lenz
Honoraria - Abbvie; Adagene; Bayer; Boehringer Ingelheim; Fulgent Genetics; Janssen Oncology; Jazz Pharmaceuticals; Merck Serono; Merus; Roche
Consulting or Advisory Role - 3T BioSciences; Abbvie; Adagene; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Volker Heinemann
Stock and Other Ownership Interests - BioNTech SE
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Merck; MSD; Novartis; Oncosil; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen; SERVIER; Sirtex Medical
Consulting or Advisory Role - Amgen; AstraZeneca; GlaxoSmithKline; Halozyme; Janssen; Merck; MSD; Nordic Bioscience; Oncosil; Pierre Fabre; Roche; Servier/Pfizer; TERUMO
Research Funding - Amgen (Inst); Merck (Inst); Roche (Inst); Servier (Inst)
Expert Testimony - Oncosil; Servier
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck; MSD; Nordic Bioscience
 
Chiara Cremolini
Honoraria - Amgen; Bayer; GlaxoSmithKline; Merck; Merck; MSD; Pierre Fabre; Roche; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; Bicara Therapeutics; MSD; Nordic Bioscience; Pierre Fabre; Revolution Medicines; Roche; Rottapharm Biotech; Takeda
Speakers' Bureau - Merck; MSD; Pierre Fabre; SERVIER
Research Funding - Bayer; Merck; Roche; SERVIER